Industry Supported Sessions Programs

Industry Supported Sessions Programs

WEDNESDAY, MARCH 27, 2019

INDUSTRY SESSION 1

FROM OFF TO ON - TREATING "OFF" EPISODES IN PARKINSON'S DISEASE

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Sunovion

Wednesday, March 27| 11:00 - 13:00 | Auditorium I

Chair: Warren Olanow (USA)        

11:00-11:10       INTRODUCTION AND OVERVIEW

11:10–11:30      PHENOMENOLOGY AND CLINICAL SIGNIFICANCE OF "OFF" EPISODES IN PD
                         Werner Poewe (Austria)
11:30–11:50      PATHOPHYSIOLOGY AND RISK FACTORS FOR THE DEVELOPMENT OF "OFF" EPISODES IN PD
                         Warren Olanow (USA)

11:50–12:10      CURRENT APPROACHES TO THE TREATMENT OF "OFF" EPISODES IN PD
                         Olivier Rascol (France)

12:10–12:30      NEW THERAPIES FOR THE ACUTE TREATMENT OF "OFF" EPISODES IN PD
                         Fabrizio Stocchi (Italy)

12:30–13:00      PANEL DISCUSSION
                          All 


INDUSTRY SESSION 2

LIPIDIDIET: CLINICAL TRIAL RESULTS FROM THE 3-YEAR INTERVENTION WITH FORTASYN CONNECT (SOUVENAID) IN PRODROMAL AD

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Nutricia

Wednesday, March 27| 15:00-15:30 | Auditorium I

Chair: Miia Kivipelto (Sweden)

15:00 – 15:05 CHAIR’S WELCOME AND INTRODUCTION 
                       Miia Kivipelto (Sweden)

15:05 - 15:15 EFFECTS OF THE SPECIFIC MULTINUTRIENT COMBINATION FORTASYN CONNECT IN PRODROMAL ALZHEIMER'S DISEASE (LIPIDIDIET): DETAILED CHARACTERISATION OF THE 36-MONTH DROPOUT PATTERN
Tobias Hartmann (Germany)

15:15- 15:30  EFFECTS OF THE SPECIFIC MULTINUTRIENT COMBINATION FORTASYN CONNECT IN PRODROMAL ALZHEIMER'S DISEASE (LIPIDIDIET): 36-MONTH INTERVENTION RESULTS
Hilkka Soininen (Finland)

THURSDAY, MARCH 28, 2019

INDUSTRY SESSION 3

DETECTING AD AND PD WITH PLASMA BIOMARKERS: INNOVATIONS THAT INFORM CLINICAL PRACTICE

SYMPOSIUM IS ORGANISED AND SUPPORTED BY MagQu Co. Ltd. 

Thursday, March 28 | 09:15 - 11:15 | Auditorium I

Chair: Kaj Blennow (Sweden)      

09:15–09:20   INTRODUCTIONS AND MEETING OBJECTIVES
                      Kaj Blennow (Sweden)

09:20–09:35   PLASMA BIOMARKERS FOR AD: THE CURRENT LANDSCAPE
                      Harald Hampel (France)

09:35–09:50   THE IMR-SQUID TECHNOLOGY PLATFORM
                      Shieh-Yueh Yang (Taiwan)

09:50–10:10   GLOBAL VALIDATION OF THE IMR ASSAY IN AD
                      Lih-Fen Lue (USA)

10:10–10:30   CORRELATION OF THE IMR ASSAY WITH IMAGING BIOMARKERS (MRI & PET)
                      Ming-Jang Chiu (Taiwan)

10:30-10:50   DIFFERENTIAL DIAGNOSIS OF THE IMR ASSAY IN AD, PD, & FTD
                      Chin-Hsien Lin (Taiwan)

10:50-11:05   HOW PLASMA BIOMARKERS MAY INFORM CLINICAL PRACTICE
                      José Luis Molinuevo (Spain)

11:05-11:15   Q&A SESSION
                      Kaj Blennow (Sweden)


INDUSTRY SESSION 4

EARLY ALZHEIMER'S DISEASE: MEETING PATIENT AND CAREGIVER NEEDS THROUGH A MULTIDISCIPLINARY APPROACH

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Roche

Thursday, March 28 | 11:45 - 13:30 | Auditorium I

Chair: Tania Dussey-Cavassini (Switzerland)

11:45 - 11:50  SYMPOSIUM ARRIVALS AND LUNCH

11:50 - 11:55  WELCOME AND INTRODUCTION
                       Tania Dussey-Cavassini (Switzerland)

11:55 - 12:05  THE CAREGIVER AND FAMILY STORY
                       Tania Dussey-Cavassini (Switzerland)

12:05 - 12:15  MEET THE PATIENT: INTERACTIVE CASE STUDY AND PANEL DISCUSSION
                       Tania Dussey-Cavassini (Switzerland)

12:15 - 12:40  THE BENEFIT OF COGNITIVE ASSESSMENTS: THE NEUROPSYCHOLOGIST'S INPUT
                       Jane Martin (USA)

12:40 - 13:00  HOW TO INCREASE DIAGNOSTIC CONFIDENCE: THE VIEW FROM A BIOMARKER EXPERT
                        Oskar Hansson (Sweden)

13:00 - 13:25  NEUROIMAGING AND THE CONFIRMATION OF DIAGNOSIS: THE NEUROLOGIST'S PERSPECTIVE
                        Marwan Sabbagh (USA)

13:25 - 13:30  A VISION OF THE FUTURE FOR ALZHEIMER'S DISEASE PATIENTS: SUMMARY AND CLOSE
                       Tania Dussey-Cavassini (Switzerland)


INDUSTRY SYMPOSIUM 6

INSIDE DEMENTIA WITH LEWY BODIES: FROM DIAGNOSIS TO CARE

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Eisai

Thursday, March 28 17:20 – 19:20 | Auditorium VI+VII 

Chair: James Galvin (USA)

17:20 – 17:30    INTRODUCTION
                         James Galvin (USA)

17:30 – 17:50    NAVIGATING THE UNKNOWN OF LEWY BODY DEMENTIAS 
                         Angela Taylor (USA)

17:50 – 18:10    DEMENTIA WITH LEWY BODIES: DIAGNOSTIC ISSUES COMPARED TO ALZHEIMER’S DISEASE
                         Ian McKeith (UK)

18:10 – 18:30    RAISING AWARENESS AND WORKING COLLABORATIVELY
                         Dag Aarsland (UK)

18:30 – 18:50    THE QUEST FOR A TREATMENT: CLINICAL STRATEGIES TO TARGET SYMPTOM CONTROL AND                             DISEASE MODIFICATION
                          James Galvin (USA)

18:50 – 19:20    Q&A SESSION
                          All

FRIDAY, MARCH 29, 2019

INDUSTRY SESSION 8

AMBAR (ALZHEIMER’S MANAGEMENT BY ALBUMIN REPLACEMENT) PHASE IIB/III RESULTS:
CLINICAL AND BIOMARKER UPDATE

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Grifols
 
Friday, March 29 | 09:15-11:15 | Auditorium VI+VII
 
Chair: Jeffrey L. Cummings (USA)
 
09:15 - 09:20   INTRODUCTION AND OVERVIEW
                        Jeffrey L. Cummings (USA)
 
09:20 - 09:40   ALBUMIN AS PHARMACEUTICAL ACTIVE INGREDIENT FOR ALZHEIMER’S DISEASE
                        Montserrat Costa (SPAIN)
 
09:40 - 10:00   PILOT AND PHASE II STUDIES ON PLASMA EXCHANGE WITH ALBUMIN REPLACEMENT IN                                  ALZHEIMER’S DISEASE
                        Óscar López (USA)
 
10:00 - 10:15   THE AMBAR STUDY DESIGN
                        Mercè Boada (SPAIN)
 
10:15 - 10:40   THE AMBAR STUDY UPDATE ON EFFICACY, SAFETY AND BIOMARKER RESULTS.
                        Antonio Páez (SPAIN)
 
10:40 - 11:10   PANEL DISCUSSION AND Q&A
                        Montserrat Costa (SPAIN)
                        Óscar López (USA)
                        Mercè Boada (SPAIN)
                        Antonio Páez (SPAIN)
                        TBA
                          
11:10 - 11:15   CONCLUDING REMARKS
                        Jeffrey L. Cummings (USA)


INDUSTRY SESSION 10

NOW YOU SEE ME: THE VOICE OF PEOPLE WITH PARKINSON'S DISEASE IN CLINICAL TRIALS
'A NEW ERA OF TREATING AND MEASURING TREATMENT OUTCOMES IN PD'

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Roche  

Friday, March 29| 15:45 - 16:45 | Auditorium I

Chair: Bas Bloem (Netherlands)     

Patient advocate speaker: Benjamin Stecher (Canada)

15:45–15:50   INTRODUCTION 
                      Bas Bloem (Netherlands)

15:50–16:10   THE REAL FACE OF PARKINSON'S DISEASE: BRINGING PARKINSON'S DISEASE CLINICAL                                        STUDIES BACK HOME
                      Bas Bloem (Netherlands)

16:10–16:20   MY PERSONAL PARKINSON’S
 
                      Benjamin Stecher (Canada)

16:20–16:35  NO ONE CAN DO THIS ALONE
                      
Audience engagement

16:35-16:40   Q&A 
                      Bas Bloem (Netherlands) and Benjamin Stecher (Canada)

16:40-16:45   SUMMARY AND CLOSE
                      Bas Bloem (Netherlands)


INDUSTRY SESSION 11

FROM MICE TO MEN: INCREASING PREDICTIVE VALUE IN CNS DRUG DEVELOPMENT

SYMPOSIUM IS ORGANISED AND SUPPORTED BY PsychoGenics / NeuroScios 

Friday, March 29| 17:15 - 19:15 | Auditorium VI+VII

Chairs:  Manfred Windisch (AUSTRIA) and Emer Leahy (USA)         


17:15–17:35    NEXT-GENERATION MOUSE MODELS OF ALZHEIMER'S DISEASE

Gregory Carter (USA)

 

17:35–17:55    HIGH CONTENT PHENOTYPING AND MACHINE LEARNING APPROACHES TO AD DRUG DISCOVERY

Emer Leahy (USA)


17:55–18:15    INSIGHTS INTO ALTERED CNS FUNCTION BY EEG BIOMARKERS: APPLICATION TO AD DRUG DISCOVERY
Steve Leiser (USA)

 

18:15–18:35    LINKING EXPERIMENTAL MODELS OF AD TO PRECLINICAL AND CLINICAL DRUG                        DEVELOPMENT PROGRAMS

                        Eliezer Masliah (USA)

 

18:35–18:55    ADVANCED MEDICAL IMAGE HANDLING AND ANALYSIS IN CNS CLINICAL TRIALS
Matt Rowe (UK)

 

18:55-19:15     DRUG DEVELOPMENT IN AD - CHALLENGES IN CLINIC AND BEHAVIORAL TESTING
Jakub Hort (CZECH REPUBLIC)